euro-cancer-2018-scientifictracks

13 / 36

Volume 10 Journal of Cancer Science & Therapy
ISSN: 1948-5956 Euro Cancer 2018
July 23-25, 2018
Page 62
conferenceseries.com
July 23-25, 2018 | Rome, Italy
29th Euro-Global Summit on
Cancer Therapy & Radiation Oncology
Christopher S Lange, J Cancer Sci Ther 2018, Volume 10
DOI: 10.4172/1948-5956-C8-144
Applying Koch’s postulates to test the cancer stem cell basis of cancer
We tested the cancer stem cell (CSC) hypothesis using the patented Hybrid Spheroid (HS) Assay (HSA) and by applying Koch’s
postulates to test its validity. The HSA is an in vitro assay that enables one to take a viable sample of an individual patient’s
tumor, make a single cell suspension, mix it in known proportions with human fibroblasts (AG1522) and dispense a known number
of cells of the mixture into each well of ultra low attachment (ULA) 96-well plates to agglomerate into 1 HS/well, each containing an
average of <1 CSC. The HS provides an analog of the CSC niche, enabling the CSC to proliferate (with some daughters differentiating
into amplifying transit cells (ATCs)) and undergo 10–15 symmetric divisions before exhausting the nutrients. This satisfies the
McCulloch and Till (spleen colony assay) requirements for a stem cell. Applying Koch’s postulates, we answer the following questions:
Does the patient’s tumor contain cells with CSC properties?; Can we isolate and propagate these cells?; Can these cells induce the
tumor in vivo?; Do these cells contain and express specific gene products that give them CSC properties?; If we disrupt these genes,
do the cells lose their CSC properties?; If we eliminate the CSCs do we eliminate the cancer? The HSA was applied to tumor samples
taken from individual endometrial adenocarcinoma patients and correctly predicted, based on CSC radioresistance, in patients who
fail their standard-of-care treatments. It was therefore concluded that the CSC hypothesis is validated in the HSA.
Biography
Christopher S Lange is the Associate Chair, Department of Radiation Oncology, SUNY Downstate Medical Center, Brooklyn (2010–Present), Professor of Molecular
and Cell Biology, School of Graduate Studies, SUNY Downstate Medical Center (1992–Present), Professor, Director, Radiobiological Division, Department of Radiation
Oncology, SUNY Downstate Medical Center (1980–Present), Associate Director, Residency Program, SUNY Downstate Medical Center (2009), Assistant Professor of
Radiology, Radiation Biology and Biophysics, University of Rochester School of Medicine and Dentistry, New York (1969–1980), NHS Senior Research Officer, Christie
Hospital and Holt Radium Institute, Manchester, England (1968–1969), NHS Research Officer, Christie Hospital and Holt Radium Institute, Manchester, England (1962–
1968), MRC Research Assistant, Radiobiology Laboratory, Churchill Hospital, Headington, England (1961–1962).
Christopher S Lange
Downstate Medical Center, Brooklyn, NY, USA